Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 2021 Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:55 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 2021 Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:55 p.m. ET. A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible for 14 days post-conference. The company focuses on developing therapeutic medicines for patients with significant unmet medical needs, including its portfolio of assets such as ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting various debilitating diseases.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was -15.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 2:55 p.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts!™ Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.